Research programme: cancer radiopharmaceuticals - Progenics Pharmaceuticals

Drug Profile

Research programme: cancer radiopharmaceuticals - Progenics Pharmaceuticals

Alternative Names: 131-I-MIP-1375; 99mTc-MIP-1340; 99mTc-MIP-1407; I-131-MIP-1095; I-131-MIP-1466; MIP-1095; MIP-1095 I-131; MIP-1340; MIP-1375; MIP-1407; MIP-1466; MIP-1555; MIP-1558; MIP-220; Radiolabelled SSTR2 agonist and antagonist peptides - Progenics; Tc-99m-PSMA inhibitors - Progenics

Latest Information Update: 04 Apr 2013

Price : $50

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Diagnostic agents; Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Prostate cancer

Most Recent Events

  • 15 Mar 2013 PSMA-targeting small-molecule therapeutics are still in preclinical trials for Prostate cancer in USA
  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 14 Jun 2012 Pharmacodynamics data from a preclinical trial in Prostate cancer released by Molecular Insight Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top